Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

efficacy assessments: * Histopathological findings based on the biopsies of the primary tumor location and the tissue excision at the end of trial (histological cure). * Description of the clinical-therapeutic effect of resiquimod on nBCC (nodular-basal cell carcinoma) by visual inspection (clinical evaluation of treatment area and assessment of complete clinical clearance) * RNA-analysis (analysis of gene expressions for cytokines, cytotoxic and apoptotic signals) * Investigator's global judgment of efficacy by means of a 7-point scale Safety assessments: * Evaluation of Adverse Events (AEs) and Serious Adverse Events (SAEs) * Evaluation of local tolerability (local skin reactions as erythema, edema, erosion/ulceration, exsudate, dryness, encrustation) by means of symptom scoring scales (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). * Evaluation of systemic tolerability \[hematology (erythrocytes, leucocytes including neutrophils, hemoglobin, hematocrit, thrombocytes), blood chemistry (alkaline phosphatase, bilirubin, aspartate transaminase (ASAT), alanine transaminase (ALAT), serum creatinine), vital signs\]. The thresholds concerning laboratory abnormalities that determine patient's discontinuation from trial were predefined upfront. * Evaluation of the number of patients withdrawn from the trial * Investigator's global judgment of tolerability by means of a 6-point scale * Photographic documentation of the treatment area Exploratory parameter: * C-reactive protein (CRP) * Interferon-alpha, interleukin-6, interleukin-12, interferon-gamma, TNF-alpha (up-regulation of gene expression) * Immunohistochemistry and characterization of cell types (CD8, T-cells, macrophages, dendritic cells) * In addition, blood serum samples will be preserved and frozen for later tests that will be specified to the patients. The preserved material will be stored for a maximum of 2 years.